How should we use convalescent plasma therapies for the management of COVID-19?

Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Wood, Erica M., Estcourt, Lise J., McQuilten, Zoe K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
BLOOD Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992504/
https://www.ncbi.nlm.nih.gov/pubmed/33202419
http://dx.doi.org/10.1182/blood.2020008903
Descripción
Sumario:Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), transfusion volume, and administration timing remain to be determined. Preliminary COVID-19 CP safety data are encouraging, but establishing the clinical efficacy of CP requires an ongoing international collaborative effort. Preliminary results from large, high-quality randomized trials have recently started to be reported.

Ejemplares similares